XML 135 R117.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segments - Schedule of Revenues by Major Products and Activities (Detail) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Product Information [Line Items]      
Revenues $ 16,544 $ 15,846 $ 14,925
United States [Member]      
Product Information [Line Items]      
Revenues 8,034 7,731 7,003
Europe [Member]      
Product Information [Line Items]      
Revenues 5,103 4,837 4,525
International Markets [Member]      
Product Information [Line Items]      
Revenues 2,463 2,351 2,352
Generic products (including OTC and biosimilars) [Member] | United States [Member]      
Product Information [Line Items]      
Revenues 3,599 3,138 3,155
Generic products (including OTC and biosimilars) [Member] | Europe [Member]      
Product Information [Line Items]      
Revenues 3,926 3,664 3,466
Generic products (including OTC and biosimilars) [Member] | International Markets [Member]      
Product Information [Line Items]      
Revenues 1,937 1,932 1,980
AJOVY [Member] | United States [Member]      
Product Information [Line Items]      
Revenues 207 211 210
AJOVY [Member] | Europe [Member]      
Product Information [Line Items]      
Revenues 216 160 124
AJOVY [Member] | International Markets [Member]      
Product Information [Line Items]      
Revenues 84 63 42
AUSTEDO [Member] | United States [Member]      
Product Information [Line Items]      
Revenues 1,642 1,225 963
AUSTEDO [Member] | International Markets [Member]      
Product Information [Line Items]      
Revenues 46 15 8
BENDEKA and TREANDA [Member] | United States [Member]      
Product Information [Line Items]      
Revenues 168 237 309
COPAXONE [Member] | United States [Member]      
Product Information [Line Items]      
Revenues 242 297 359
COPAXONE [Member] | Europe [Member]      
Product Information [Line Items]      
Revenues 213 231 268
COPAXONE [Member] | International Markets [Member]      
Product Information [Line Items]      
Revenues 48 63 64
UZEDY [Member] | United States [Member]      
Product Information [Line Items]      
Revenues 117 23 0
Anda [Member] | United States [Member]      
Product Information [Line Items]      
Revenues 1,536 1,577 1,471
Respiratory Product [Member] | Europe [Member]      
Product Information [Line Items]      
Revenues 244 265 273
Other [Member] | United States [Member]      
Product Information [Line Items]      
Revenues [1] 523 1,025 536
Other [Member] | Europe [Member]      
Product Information [Line Items]      
Revenues [2] 504 516 393
Other [Member] | International Markets [Member]      
Product Information [Line Items]      
Revenues [3] $ 349 $ 278 $ 257
[1] Other revenues in 2024 include the sale of certain product rights. Other revenues in 2023 were mainly comprised of a $500 million upfront payment received in the fourth quarter of 2023, in connection with the collaboration on Teva’s duvakitug (anti-TL1A) asset (see note 2).
[2] Other revenues in 2024 and 2023 include the sale of certain product rights.
[3] Other revenues in 2024 include the sale of certain product rights.